Become a Reviewer | Current Medicinal Chemistry 

Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews and guest edited thematic issues written by leaders in the field covering a range of the current topics in medicinal chemistry. The journal also publishes reviews on recent patents. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.

Abstracted and Indexed in:

  • Science Citation Index®
  • Journal Citation Reports/Science Edition
  • InCites
  • Science Citation Index Expanded
  • Index to Scientific Reviews®
  • Biochemistry and Biophysics Citation Index®
  • Current Contents® – Life Sciences
  • Research Alert
  • BIOSIS
  • BIOSIS Previews
  • BIOSIS Reviews Reports and Meetings
  • Prous Science Integrity®
  • MEDLINE/PubMed/Index Medicus
  • Scopus
  • EMBASE/Excerpta Medica
  • Chemical Abstracts Service/SciFinder
  • ProQuest
  • ChemWeb
  • Google Scholar
  • BIOBASE
  • Reference Update
  • PubsHub
  • Index Copernicus
  • MediaFinder®-Standard Periodical Directory
  • Genamics JournalSeek
  • J-Gate
  • CNKI Scholar
  • Suweco CZ
  • TOC Premier
  • EBSCO
  • British Library
  • Ulrich’s Periodicals Directory
  • JournalTOCs

The Journal “Current Medicinal Chemistry” is interested in appointing active Reviewers on the Journal’s Board. If you are working in the field mentioned and are interested in becoming an Reviewer, send your CV and a list of publications at the below mentioned email. If the scope of the journal is not directly related to your field of interest then please feel free to recommend suitable colleagues for the Reviewer of the journal and send us their CV and a list of publications, if possible.

Submit your CV at your earliest convenience at hermain@benthamscience.net and CC faizan@benthamscience.net, mentioning in the subject line your field of interest. The responsibilities of Reviewer will be discussed in detail further once the CV is received.

 

reviewer-banner-

 

Become an Editorial Board Member (EBM) | Current Medicinal Chemistry 

Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews and guest edited thematic issues written by leaders in the field covering a range of the current topics in medicinal chemistry. The journal also publishes reviews on recent patents. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.

Abstracted and Indexed in:

  • Science Citation Index®
  • Journal Citation Reports/Science Edition
  • InCites
  • Science Citation Index Expanded
  • Index to Scientific Reviews®
  • Biochemistry and Biophysics Citation Index®
  • Current Contents® – Life Sciences
  • Research Alert
  • BIOSIS
  • BIOSIS Previews
  • BIOSIS Reviews Reports and Meetings
  • Prous Science Integrity®
  • MEDLINE/PubMed/Index Medicus
  • Scopus
  • EMBASE/Excerpta Medica
  • Chemical Abstracts Service/SciFinder
  • ProQuest
  • ChemWeb
  • Google Scholar
  • BIOBASE
  • Reference Update
  • PubsHub
  • Index Copernicus
  • MediaFinder®-Standard Periodical Directory
  • Genamics JournalSeek
  • J-Gate
  • CNKI Scholar
  • Suweco CZ
  • TOC Premier
  • EBSCO
  • British Library
  • Ulrich’s Periodicals Directory
  • JournalTOCs

The Journal “Current Medicinal Chemistry” is interested in appointing active Editorial Board Members on the Journal’s Board. If you are working in the field mentioned and are interested in becoming an Editorial Board Member, send your CV and a list of publications at the below mentioned email. If the scope of the journal is not directly related to your field of interest then please feel free to recommend suitable colleagues for the Editorial Board Members of the journal and send us their CV CV and a list of publications, if possible.

Submit your CV at your earliest convenience at hermain@benthamscience.net and CC faizan@benthamscience.net, mentioning in the subject line your field of interest. The responsibilities of Editorial Board Members will be discussed in detail further once the CV is received.

 

banner

EDITORS CHOICE ARTICLE – PARP Inhibitors in Ovarian Cancer

Journal Name: Recent Patents on Anti-Cancer Drug Discovery 

Author(s): Gloria Mittica, Eleonora Ghisoni, Gaia Giannone, Sofia Genta, Massimo Aglietta, Anna Sapino, Giorgio Valabrega*.

 

 

Abstract:

Background: Treatment of Epithelial Ovarian Cancer (EOC), historically based on surgery and platinum doublet chemotherapy, is associated with high risk of relapse and poor prognosis for recurrent disease. In this landscape, the innovative treatment with PARP inhibitors (PARPis) demonstrated an outstanding activity in EOC, and is currently changing clinical practice in BRCA mutant patients.

Objectives: The study aimed to highlight the mechanism of action, pharmacokinetics, clinical activity, indications and current strategies of development of Olaparib, Niraparib, Rucaparib, Talazoparib and Veliparib, the 5 most relevant PARPis.

Methods: We performed a review on Pubmed using ‘ovarian cancer’ and the name of each PARPi (PARP inhibitor) discussed in the review as Medical Subject Headings (MeSH) keywords. The same search was performed on “clinicaltrial.gov” to identify ongoing clinical trials and on “google. com/patents” and “uspto.gov” for recent patents exploring PARPIs in ovarian cancer.

Results: Olaparib, Niraparib and Rucaparib are already approved for the treatment of recurrent EOC and their indications are partially overlapping. Talazoparib and Veliparib are promising PARPis, but currently under investigation in early phase trials. Several studies are evaluating PARPis in monotherapy or in associations, in a wide range of settings (i.e. first line, neoadjuvant, platinum-sensitive and resistant disease).

Conclusion: PARPis are valuable options in patients with recurrent ovarian cancer with promising activity in different stages of this disease. Further studies are required to better define optimal clinical settings, predictors of response beyond BRCA mutations and strategies to overcome secondary resistance of PARPis therapy in EOC.

 

For more details, please visit: http://www.eurekaselect.com/160235/article

RECENTLY PUBLISHED ISSUES – BENTHAM SCIENCE JOURNALS

CNS & Neurological Disorders – Drug Targets 16-7

http://bit.ly/2i2fEOA

Current Physical Chemistry 7-3

http://bit.ly/2AKGPoB

Adolescent Psychiatry  7-1

http://bit.ly/2jBiqah

Current Molecular Medicine  17-3

http://bit.ly/2ka4SpY

Current Topics in Medicinal Chemistry  17-26

http://bit.ly/2zRRhKV

Current Diabetes Reviews   13-6

http://bit.ly/2ALkFCQ

Current Drug Metabolism  18-8

http://bit.ly/2kdV4eK

Current Respiratory Medicine Reviews  13-1

http://bit.ly/2BrLwjp

Current Alternative Energy  1-1

http://bit.ly/2iui8VY

Medicinal Chemistry  13-7

http://bit.ly/2AhCnwO

Current Drug Delivery 14 -7

http://bit.ly/2zFFlrD

Current Drug Targets 18 -15

http://bit.ly/2ALanm6

Current Nanoscience 13-6

http://bit.ly/2i7JE84

Combinatorial Chemistry & High Throughput Screening 20-6

http://bit.ly/2ivNMm6

recent-issues

 

 

 

 

 

Important Announcement

ImageMay 2014 issue of the journal Recent Patents Anti-Cancer Drug Discovery is now available online, you can have a look at it via: http://benthamscience.com/journal/index.php?journalID=rpacdd

 

 

 

 

ImageJanuary 2014 issue of the journal Recent Patents on Biomarkers is now available online, have a look at it via: http://benthamscience.com/journal/index.php?journalID=rpbm

 

 

 

 

ImageJanuary 2014 issue of the journal Recent Patents on Regenerative Medicine is now available online, have a look at it via: http://benthamscience.com/journal/index.php?journalID=rprm

Podcast by Dr. Marina

Journal Name: Recent Patents on Anti-Infective Drug Discovery
Vol.8, No. 2, 2013
Article: “Photosensitizers as an alternative to antibiotics.
Author: Dr. Marina Nisnevitch

Author’s Testimonial!

ImageI can only find the very best words for everyone at Bentham Science Publishers whom I have worked with, starting with the editor-in-chief of Recent Patents on Biomarkers, the publications manager, and also all other people involved in the publishing process. Everyone is working with the utmost professionalism, knowledge and skill. I can only commend the quality and precision with which the work is being done by the Recent Patents on Biomarkers team.

 

Dr. Orfeas Liangos

Med. Klinik III., Klinikum

Coburg, 

Germany

September 2013 issue of the journal Recent Patents on Biomarker is now available online!!

Recent Patents on Biomarkers publishes review and research articles, and guest edited thematic issues on important recent patents on biomarkers. The coverage includes novel biomarkers in basic, medical, environmental, and pharmaceutical research. A selection of important and recent patents on biomarkers is also included in the journal. The journal is essential reading for all researchers involved in biomarker research and discovery. The journal also covers recent research (where patents have been registered) in fast emerging patent biomarker applications; discovery and validation are covered for drug discovery, clinical development and molecular diagnostics.

The journal is indexed in Chemical Abstracts, MediaFinder®-Standard Periodical Directory, J-Gate, PubsHub, CABI.

Executive Editor: Khurshid Zaman

Associate Editor: Angel G. Martin

Regional Editor: William C.S. Cho

Image

%d bloggers like this: